Brendan O’Malley, J.D., Ph.D., joined Abeona in 2019 as Chief IP Counsel, bringing significant technical and legal expertise to the Abeona team. Prior to joining Abeona, he was a partner at the prominent New York patent litigation firm Fitzpatrick Cella Harper & Scinto, where he started his career as a summer associate in 2006, and then at Venable LLP, which merged with Fitzpatrick in 2018. While at Fitzpatrick and Venable, Dr. O’Malley litigated a wide variety of biopharmaceutical patent cases in the United States District Courts, at the Federal Circuit, and before the U.S. Patent and Trademark Office, negotiated numerous settlement and license agreements, and provided many patent opinions in connection with M&A due diligence in the biotech space.
While attending law school at Benjamin N. Cardozo School of Law, Dr. O’Malley served as a judicial intern to Judge William H. Pauley in the U.S. District Court for the Southern District of New York.
Before law school, he earned a Ph.D. in Molecular Biology & Microbiology from Tufts University School of Medicine, where he studied the role of protein-protein interactions in hepatitis virus assembly, and a B.S. degree magna cum laude from the University of Massachusetts Dartmouth.
What is Brendan M. O'Malley's net worth?
The estimated net worth of Brendan M. O'Malley is at least $1.71 million as of September 29th, 2025. Mr. O'Malley owns 350,763 shares of Abeona Therapeutics stock worth more than $1,708,216 as of December 5th. This net worth evaluation does not reflect any other investments that Mr. O'Malley may own. Learn More about Brendan M. O'Malley's net worth.
How do I contact Brendan M. O'Malley?
Has Brendan M. O'Malley been buying or selling shares of Abeona Therapeutics?
Brendan M. O'Malley has not been actively trading shares of Abeona Therapeutics during the past quarter. Most recently, Brendan M. O'malley sold 9,366 shares of the business's stock in a transaction on Monday, September 29th. The shares were sold at an average price of $5.39, for a transaction totalling $50,482.74. Following the completion of the sale, the senior vice president now directly owns 350,763 shares of the company's stock, valued at $1,890,612.57. Learn More on Brendan M. O'Malley's trading history.
Who are Abeona Therapeutics' active insiders?
Are insiders buying or selling shares of Abeona Therapeutics?
During the last twelve months, insiders at the biopharmaceutical company sold shares 22 times. They sold a total of 351,238 shares worth more than $2,047,717.92. The most recent insider tranaction occured on November, 13th when Director Mark Alvino sold 15,000 shares worth more than $71,100.00. Insiders at Abeona Therapeutics own 6.9% of the company.
Learn More about insider trades at Abeona Therapeutics. Information on this page was last updated on 11/13/2025.
